Birgitta E Michels

Plain English
This study looked at the link between human herpesvirus 7 and the risk of developing multiple sclerosis (MS). Researchers found that people who had evidence of human herpesvirus 7 were more than twice as likely to develop MS compared to those who didn’t, with an odds ratio of 2.2. This is important because it helps identify potential risk factors for MS, which could lead to better prevention or treatment strategies. Who this helps: This benefits researchers and healthcare professionals seeking to understand and address the risk factors for multiple sclerosis.

Plain English
Researchers developed a blood test that detects HPV cancer DNA years before oropharyngeal cancer (a common throat cancer) develops, finding the virus DNA in 79% of patient blood samples taken up to 7.8 years before diagnosis, while showing no false positives in healthy people. Using advanced computer analysis, they improved the test to detect the cancer signal in 96% of cases up to 10 years before symptoms appear. This discovery could enable doctors to catch this aggressive cancer much earlier, when treatment is more likely to succeed and causes less harm.

Plain English
This study looked at a specific molecule called pre-miR-1307 and its roles in breast cancer. Researchers found that when a part of this molecule, called miR-1307-5p, was highly active, it actually slowed down tumor growth and blood vessel formation in breast cancer cells. This is important because it shows that targeting this molecule could lead to new treatments that help fight against breast cancer. Who this helps: This could benefit breast cancer patients by leading to new therapeutic options.

Plain English
This study looked at the long-term presence of specific antibodies in pregnant women and men that indicate prior infections with certain sexually transmitted infections (STIs). The researchers found that 30.4% of women and 17.4% of men had these persistent antibodies, with higher numbers linked to having more sexual partners, engaging in anal sex, and a history of diagnosed STIs. Understanding these risk factors is crucial for developing better prevention and care strategies for STIs. Who this helps: This helps patients at risk for STIs, healthcare providers, and public health officials.

Plain English
This study looked at the presence of specific antibodies, called HPV16 E6, in 2,320 men living with HIV in Tennessee, to find out how common these antibodies are and what factors might be linked to their presence. The researchers found that 5.6% of the men had these antibodies, with a notable portion showing moderate or high levels—2.4% had moderate and 3.2% had high levels. This is important because it highlights a higher prevalence of HPV16 E6 antibodies in this group compared to previous studies, suggesting a greater risk for HPV-related throat cancers, especially in the Southeast U.S., which has high rates of HIV and these cancers. Who this helps: This helps patients living with HIV by providing insight into their risk for HPV-related health issues.

Plain English
This study looked at how mothers pass antibodies for the infections Chlamydia trachomatis and Mycoplasma genitalium to their newborns, and how these antibodies change as the child grows in the first three years of life. Researchers followed 309 mother-baby pairs, finding that most mothers transferred antibodies to their babies, but only a few children developed their own antibodies later—2.1% for Chlamydia and 0.4% for Mycoplasma at three years old. Understanding how these antibodies work can help improve care for children born to mothers with these infections. Who this helps: This helps doctors and health professionals working with expectant mothers and young children.

Plain English
This study looked at men living with HIV and how the presence of antibodies against a particular type of human papillomavirus (HPV16) relates to the risk of oropharyngeal cancer, which affects the throat. They found that men with HPV16 E6 antibodies had a 14 times greater chance of developing oropharyngeal cancer compared to those without these antibodies. Specifically, 45% of the cancer cases studied had these antibodies, while only 6% of controls did. Who this helps: This research benefits men living with HIV by improving understanding of their cancer risks.

Plain English
This study looked at how infections from Mycoplasma genitalium (Mg) and human papillomavirus (HPV) interact in couples. The researchers followed 329 women and their 135 male partners over three years and found that women with high levels of antibodies to Mg were more likely to develop new oral HPV infections, with a risk increase of over four times (OR 4.14). Additionally, having these antibodies was linked to a greater likelihood of being positive for high-risk HPV after follow-up, with odds ranging from about 2.66 to 4.62. Who this helps: This research helps patients, especially women, understand the potential risks of HPV related to Mycoplasma genitalium infections.

Plain English
Researchers developed a blood test that can detect a common cancer caused by HPV (the virus linked to cervical cancer) years before symptoms appear—up to 10 years early in some cases. The test works by finding tiny pieces of HPV DNA floating in the bloodstream, which the cancer releases long before the disease becomes noticeable. When they tested blood samples taken years before patients were actually diagnosed with cancer, the test caught 79% of future cancer cases while giving zero false alarms in healthy people. Using artificial intelligence to analyze the blood samples improved detection even further, catching 96% of cases. This matters because unlike cervical cancer, there's currently no screening test for this type of HPV-related throat cancer—the most common HPV cancer in America. A blood test that finds it a decade early could save lives by catching cancer when it's easiest to treat.

Plain English
This study looked at how a protein called Scribble interacts with a cell adhesion protein known as TMIGD1. Researchers found that TMIGD1 helps move Scribble to the cell membrane, which is important because Scribble helps prevent tumor growth. Understanding how these proteins work together could lead to better insights into cancer development and prevention. Who this helps: This helps researchers and doctors working on cancer therapies.

Plain English
This study looked at how the environment around colorectal cancer tumors affects treatment responses. Researchers created a biobank with tumor organoids and cancer-associated cells from 30 patients, finding that these cells respond differently to therapies based on their surroundings. Specifically, they discovered that a subgroup of tumors showed resistance to certain drugs, like gefitinib and SN-38, highlighting the importance of understanding these interactions for better treatment outcomes. Who this helps: This research helps patients with colorectal cancer by improving treatment strategies tailored to their specific tumor characteristics.

Plain English
This study looked at the differences within breast cancer tumors, specifically those that are estrogen receptor positive, to understand why some treatments fail. Researchers developed specific models of breast cancer that became resistant to standard therapies and found that different clones of cancer cells behaved differently, showing unique responses to certain treatments. They identified that some clones were more vulnerable to blocking proteins involved in cancer cell survival, hinting at new treatment paths. Who this helps: This benefits patients with estrogen receptor positive breast cancer by helping tailor more effective therapies for their specific cancer.

Plain English
This study looked at a specific type of small RNA, called 5'isomiR-183-5p|+2, to see how it affects breast cancer cells, particularly in a tough form known as triple-negative breast cancer (TNBC). Researchers found that when they increased the levels of this isomiR, cancer cells grew slower and spread less, especially showing a significant drop in cell growth and invasion. This matters because it highlights a new way to potentially control tumor growth by understanding how different forms of a specific RNA impact cancer behavior. Who this helps: This helps patients with triple-negative breast cancer and their doctors by providing insights into potential new treatments.

Plain English
This study focused on how the tiny, finger-like structures called microvilli in the intestines, which help absorb nutrients, are formed and maintained. Researchers discovered a new adhesion complex that uses a protein called TMIGD1, which works with other proteins to keep microvilli organized. When they disabled TMIGD1 in mice, the microvilli became damaged, leading to issues with nutrient absorption. Who this helps: Patients with intestinal disorders can benefit from a better understanding of how microvilli function.

Plain English
This study looked at how different factors from various labs affected the data on small RNA molecules called isomiRs, which are important in cancer research. Researchers found that after correcting for these lab-related biases, they could clearly see that important cancer-fighting isomiRs were less active in lung tumors compared to normal tissue. This shows that without correcting the data, significant insights about cancer could be missed, and the corrected datasets now serve as a valuable resource for further cancer studies. Who this helps: This helps cancer researchers and doctors studying isomiRs and their role in cancer.

Plain English
Researchers studied how specific genetic changes in human colon cells can affect colorectal cancer, focusing on a technique called CRISPR-Cas9. They found that a gene called TGFBR2 is key in suppressing tumor growth, identifying it as the most significant factor among several that influence cancer development. This work matters because it helps scientists understand the genetic factors driving colorectal cancer, potentially leading to new treatments. Who this helps: Patients with colorectal cancer and their doctors.

Plain English
This study looked at how blocking a specific immune receptor called S1PR4 can slow down tumor growth and make chemotherapy more effective. In experiments on mice with breast and colon cancer, removing S1PR4 led to a significant increase in CD8+ T cells, which are important for fighting cancer, and these changes resulted in improved tumor control. Specifically, the research showed that disrupting this receptor delayed tumor development and enhanced the response to therapy. Who this helps: This benefits cancer patients by potentially improving treatment outcomes.

Plain English
This study looked at a specific type of colorectal cancer and how a protein called AKT affects tumor growth and spread. Researchers found that activating AKT in mice led to more aggressive tumors that were similar to a serious form of human colorectal cancer, known as CMS4, which has the lowest survival rates. They discovered that blocking another protein, NOTCH3, reduced tumor spread in the mice, suggesting that targeting NOTCH3 could benefit patients with this aggressive cancer. Who this helps: This helps patients with advanced colorectal cancer, particularly those with the CMS4 subtype.

Plain English
This study focused on how a specific signaling pathway, called Wnt, affects the cells surrounding tumors in colorectal cancer. Researchers found that when a blocker of Wnt was introduced, tumor growth in mice decreased significantly. Specifically, blocking Wnt activity reduced cancer-associated fibroblasts, which helped limit tumor aggression and promoted different cell behaviors that can affect cancer development. Who this helps: This benefits patients with colorectal cancer by potentially leading to new treatment strategies.

Plain English
Researchers studied a protein called FUBP1 and its role in two types of leukemia: chronic myeloid leukemia (CML) and acute myeloid leukemia (AML). They found that reducing FUBP1 levels in lab tests and mouse models led to longer survival and fewer leukemia cells; specifically, there was a decrease in CML progenitor cells and increased cell death in leukemia cells with less FUBP1. This matters because higher levels of FUBP1 were linked to worse outcomes in patients, and blocking FUBP1 or treating with certain drugs improved survival in mice with leukemia. Who this helps: Patients with leukemia.

Plain English
This study looked at how different Wnt signals impact colon cells and their behavior in colorectal cancer. Researchers found two unique profiles: one linked to healthy cells and adenomas, and the other tied to cancerous tumors. Notably, stronger oncogenic Wnt signals indicated a better outcome for patients with certain types of tumors, while regular receptor signals were associated with worse prognosis. Who this helps: This research benefits patients with colorectal cancer and doctors by providing new insights for more accurate treatment strategies.

Plain English
This study explored a new way to test an innovative cancer treatment called CAR immunotherapy using 3D colon cancer models made from patients' own tumor cells. Researchers found that CAR-engineered cells effectively targeted cancer cells when looking at organoids, a small, simplified version of a tumor, especially those showing certain cancer markers. This is important because it helps develop personalized treatments that are more effective against colorectal cancer. Who this helps: This research benefits patients with colorectal cancer by paving the way for targeted and effective immunotherapies.

Plain English
This study looked at microvillus inclusion disease (MVID), a rare condition that affects how the intestines absorb nutrients. Researchers created a 3D model using intestinal organoids from mice to better understand how cells differentiating into absorptive cells develop the abnormal structures related to MVID. They found that a key protein, MUNC18-2, could restore normal function, but a variant linked to the disease did not work; they also noted that defects in the cells began appearing during the early stages of cell development and worsened as cells matured. Who this helps: This research benefits doctors and scientists working to treat patients with microvillus inclusion disease.